Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy 2026 | The increasing role of NGS in multiple myeloma

Meral Beksaç, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses the growing role of next-generation sequencing (NGS) in multiple myeloma, including risk assessment at diagnosis and identifying mutations relevant to immunotherapy selection at relapse. She highlights how genomic profiling is supporting more personalized treatment approaches in clinical practice. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So the thing is, the recent CGS classification, which is the IMS-IMWG classification, integrates NGS at diagnosis. But as you say, it’s not possible everywhere. The standard FISH, when it comes to cost, is now becoming comparable to NGS, so I would recommend and urge all reference centers to collaborate with community doctors for such tests, and that will not only make the patients get access to such very important data, but also make the tests become even cheaper...

So the thing is, the recent CGS classification, which is the IMS-IMWG classification, integrates NGS at diagnosis. But as you say, it’s not possible everywhere. The standard FISH, when it comes to cost, is now becoming comparable to NGS, so I would recommend and urge all reference centers to collaborate with community doctors for such tests, and that will not only make the patients get access to such very important data, but also make the tests become even cheaper. So with the newer NGS techniques, now it’s not only the prognostic determination, but also to check for at relapse mainly for mutations which are very relevant to immunotherapies. So these are all together in one package, which is really very helpful in designing the next treatment. So it’s a step towards personalization or individualization of treatment.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.